U.S. markets closed

Jaguar Health, Inc. (JAGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3580-0.0133 (-3.58%)
At close: 4:00PM EDT

Jaguar Health, Inc.

201 Mission Street
Suite 2375
San Francisco, CA 94105
United States
415 371 8300
http://www.jaguar.health

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Ms. Lisa A. ConteFounder, CEO, Pres & Director515.23kN/A1959
Mr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & Gen. Counsel293.06kN/A1962
Dr. Steven R. KingChief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.323.67kN/A1958
Ms. Carol R. LizakSr. VP of Fin. & Chief Accounting OfficerN/AN/A1964
Dr. Pravin R. ChaturvediChair of Scientific Advisory Board & Acting Chief Scientific OfficerN/AN/A1963
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Corporate Governance

Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.